Marit Sjo Lorentzen
Chief Operating Officer chez ARCTICZYMES TECHNOLOGIES ASA
Fortune : 55 306 $ au 31/03/2024
Profil
Marit Sjo Lorentzen is currently the Director at Biotec BetaGlucans AS and the Vice President-Operations at ArcticZymes Technologies ASA. She has an undergraduate degree from the University of Tromso.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2023 | 20 331 ( 0,04% ) | 55 306 $ | 31/03/2024 |
Postes actifs de Marit Sjo Lorentzen
| Sociétés | Poste | Début |
|---|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Chief Operating Officer | - |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Director/Board Member | - |
Formation de Marit Sjo Lorentzen
| University of Tromso | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
| Entreprise privées | 1 |
|---|---|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The private company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |
